Summary of "Unpacking OpenAI for Government Engagements"

Podcast: The AI Podcast
Host: The AI Podcast
Release Date: June 9, 2025

Introduction

In the June 9, 2025 episode of The AI Podcast, the host delves into OpenAI's strategic initiatives aimed at government collaborations. The episode explores two significant developments: OpenAI for Countries and OpenAI's partnership with the U.S. Food and Drug Administration (FDA) to accelerate drug development using artificial intelligence.

OpenAI for Countries

Launch of "OpenAI for Countries":
OpenAI has announced a new program titled "OpenAI for Countries", designed to forge partnerships with governments worldwide. This initiative aims to build and enhance local AI infrastructure tailored to each country's unique needs.

Infrastructure Development: OpenAI plans to collaborate with governments to establish data centers and customize AI tools that cater to specific languages, cultural nuances, and national requirements.

"OpenAI for countries... they're hoping to work with and be funded by the governments of, I would assume, eventually every country in the world to build out infrastructure projects to work on things within their country." ([05:30])
Funding and Partnerships: The program seeks governmental funding to support these infrastructure projects. By offering customized AI solutions, OpenAI intends to secure financial backing from participating nations.

"They can essentially try to charge more and ask countries to contribute or sponsor OpenAI, or pay a little bit of money, because they're like, look, we're going to build some, you know, special things for your particular language, for your particular culture, for your particular country's needs." ([07:15])
Strategic Goals: A primary objective of this initiative is to promote what OpenAI terms as "democratic AI", positioning their models as open and less restrictive compared to competitors like China's Deep Seek.

"Their hope with all of this is to spread democratic AI... we're more open. We're, we're a democratic AI." ([08:45])
Global Positioning: By emphasizing the openness and adaptability of their AI models, OpenAI aims to distinguish itself from authoritarian AI models, thereby appealing to democratic nations seeking reliable and customizable AI solutions.

"We're not an authoritarian AI... it's like less of a squabble about that and all of a sudden opening eyes, like, look, we're not Chinese." ([09:20])
Initial Rollout: OpenAI plans to initiate the program with approximately ten international projects, though specific locations have yet to be disclosed. This initial phase is expected to lay the groundwork for broader global engagement.

"The goal right now, they said, is to find about 10 international projects to start with." ([06:00])
Complementing Existing Projects: This program complements OpenAI's existing Stargate project, a substantial data center initiative in partnership with notable entities like Oracle and governmental figures.

"This is going to complement what they're doing with their Stargate project... build up this massive data center project in the United States." ([10:10])

Collaboration with the FDA: Accelerating Drug Development

Project Overview:
OpenAI is actively collaborating with the U.S. FDA to streamline and expedite the drug development and approval process through advanced AI tools. The initiative, referred to as "CDER GPT", is tailored for the Center for Drug Evaluation and Research (CDER) within the FDA.

Objective: The primary aim is to leverage AI to reduce the lengthy timelines traditionally associated with drug trials and regulatory approvals, potentially cutting down development periods from up to a decade to a significantly shorter timeframe.

"OpenAI is hoping to work with the FDA to essentially accelerate a portion of that timeline." ([12:05])
Functionality of CDER GPT: This AI tool is designed to assist in various aspects of drug evaluation, including data analysis, trial management, and administrative tasks, thereby enhancing efficiency and accuracy in the approval process.

"AI is going to try to make this whole drug discovery process a little bit faster and a lot of the administration stuff faster as well." ([13:50])
Stakeholder Involvement: The project involves collaboration with officials from the Department of Government Efficiency, ensuring that the AI integration aligns with regulatory standards and operational protocols.

"Some associates from the Department of Government Efficiency have been part of talks with this as well." ([12:30])
Impact on Drug Development: By incorporating AI into the drug evaluation pipeline, OpenAI and the FDA aim to foster innovation, reduce costs, and bring lifesaving medications to the market more swiftly. This could lead to faster cures and improved outcomes for various diseases.

"This is very interesting and I think we're going to start seeing hopefully faster drug time turnarounds... better outcomes on all of that." ([14:20])

Implications and Future Prospects

Enhanced Government-AI Collaborations:
OpenAI's initiatives signify a strategic pivot towards deeper government partnerships, emphasizing the role of AI in public sector efficiency and innovation. By aligning with governmental bodies, OpenAI not only secures funding but also positions itself as a pivotal player in national infrastructure development.

Competitive Edge: The emphasis on "democratic AI" serves as a competitive differentiator against non-Western AI models, potentially influencing global AI adoption trends in favor of OpenAI's offerings.

"It's kind of less of a squabble about that and all of a sudden opening eyes, like, look, we're not Chinese." ([09:20])
Scalability: With the initial rollout of ten projects, OpenAI sets the stage for scalable government collaborations, which could span various sectors beyond drug development, including education, transportation, and public safety.
Technological Advancements: These partnerships are likely to drive advancements in AI technology, particularly in creating models that are more adaptable, secure, and tailored to specific governmental needs.
Ethical and Regulatory Considerations: As OpenAI integrates more deeply with governmental agencies, issues related to AI ethics, data privacy, and regulatory compliance will become increasingly pertinent, necessitating transparent and responsible AI practices.

Conclusion

The episode underscores OpenAI's strategic initiatives to embed artificial intelligence within governmental frameworks globally. Through programs like "OpenAI for Countries" and collaborations with the FDA, OpenAI is positioning itself at the forefront of AI-driven infrastructure and innovation. These efforts not only aim to enhance operational efficiencies within governments but also seek to establish OpenAI as a leader in promoting democratic and adaptable AI solutions on a global scale.

"I think this is a great spin for them... they can kind of pin themselves in a new way." ([09:50])

As governments worldwide embrace AI technologies, OpenAI's proactive engagement and tailored solutions could significantly influence the future landscape of artificial intelligence in the public sector.

Note: For a more comprehensive understanding, listeners are encouraged to tune into the full episode of The AI Podcast.

Transcript

A (0:00)

Today on the podcast, I want to talk about OpenAI. Some big news out of them and governments, governments all over the world. OpenAI is launching something called OpenAI for countries, which is very interesting and essentially they're hoping to work with and be funded by the governments of, I would assume eventually every country in the world to build out infrastructure projects to work on things within their country. So that's fascinating. And in another vein of government, OpenAI is currently working with the FDA in the United States, the Federal Drug Administration Administration, to speed up the development of drugs with OpenAI and other AI tools. So both of these stories are really interesting. As OpenAI, I think, is looking to expand its usage, it's going directly to governments, and I think beyond just usage, it needs more money. And it knows the number one way it's going to be able to get this is if it can make special partnerships with different countries, have the countries put in money and they have a bunch of bells and whistles and things that they, they've said they'll add for countries, which I think are really fascinating. We're going to get into all of that. Before we do, I am so excited to announce that AI Box, my own software company that I've been working on for two and a half years, you probably heard me mention it 100 times, telling you to get on the wait list. And it's coming soon and we're doing some great stuff. Has officially launched our first product ever in beta. It is called the Open or the Air Box Playground. And essentially it allows you to Access the top 20 models in text, image and audio on the same chat for $20 a month. So instead of paying 20 bucks a month for 10 different subscriptions, you pay it once you get access to everything. And you can switch your switch out your AI model. You can talk to Anthropic Cloud, you can talk to Grok, you can talk to OpenAI all in the same chat, switch between them. You can also compare chat side by side. So you ask it a question and you're like, hey, I don't really like the response from Grok. Let me get ChatGPT and Anthropic to respond as well. You pick your favorite and you move on with your conversation. You can then get it to generate images with the different image models. You could get it to generate audio all within the same chat. It. It's really cool. It also has a section for media storage. So essentially everything that you've ever generated as far as media, it's all inside of your media storage tab. So you're never going to lose it in the future, right? I generate things on ChatGPT all the time, like images for thumbnails and I'm like, where did I, you know, where was that picture? I'm trying to scroll back and, like, search through my chat history, which is like, impossible on chat gbt. All of that will just be inside of your media storage. You can go click on any image you generated and it will take. And click a link. It'll take you straight back to whatever chat you were on. You can download it, you could delete it, whatever you want to do. So really, really cool. I hope it's exciting and super useful for you. You could check it out. There's a link in the description to AI box. AI. All right, let's get into what OpenAI is doing. The big thing here that I'm super excited about is kind of this, this new program, OpenAI for countries. So essentially what this is going to allow them to do is build out what they're calling local infrastructure, which they're saying is needed to serve international AI customers. So part of this program, OpenAI is essentially going to partner with governments, they're going to help them with building out data center capacity and also customizing OpenAI's products. Now, this is where I think they, they can essentially try to charge more and ask countries to contribute or sponsor OpenAI, or pay a little bit of money, because they're like, look, we're going to build some, you know, special things for your particular language, for your particular culture, for your particular country's needs. We can customize ChatGPT for you, which I think is really interesting. And then they would like the governments to help fund this, of course. So the goal right now, they said, is to find about 10 international projects to start with. They're going to start with 10. They haven't said where those are going to be located yet, but that's kind of their first goal. And they said that their hope with all of this is to, quote, spread democratic AI. Which essentially what this means is they're going to try to convince countries to use Western AI models instead of Chinese competitors, Deep Seek and other AI models out of China. It's kind of interesting. It's like ever since Deep Seat came out, I actually think it was like a great catalyst for OpenAI, because now they're like, look like we're not the bad guy compared to whatever squabbles, Grok or Google or Meta might all have about who's open source, who's not who's less, you know, censorship, who's not, whatever. So it's like less of a squabble about that and all of a sudden opening eyes, like, look, we're not Chinese, like, very blatantly, strictly censoring what goes into the model or, you know, you have to pay a massive fine. Like, we're, we're, you know, we're more open. We're, we're a democratic AI. We're not an authoritarian, you know, authoritarian, authoritative AI. Whatever, whatever. I cannot think of the word. But what's been accusing China of being authoritarian. They're not an authoritarian AI. There we go. So I think this is a great spin for them. And yeah, honestly, in that case, like, in that framing, deep sequence, probably one of the best things that could have happened to them. A big, you know, a big breakthrough out of China where they're like, look, now we got this, like, competitor there. They can kind of pin themselves in a new way. So this is interesting. And they're going to try to be getting countries to pay for this. So according to Bloomberg, this is going to be essentially something that's going to complement what they're doing with their Stargate project. This is something they announced, they had a big press conference with Oracle's CEO and Donald Trump in the White House where they said they're going to end, of course, SoftBank CEO, and they said they're going to spend $500 billion to build up this massive data center project in the United States. So it's kind of going to complement that. They also said that they might lean on Stargate infrastructure for the Open Air for Countries program, and even some of the funding from some of those investors might be used. So that is pretty interesting. All right, let's get into what's going on with the Federal Drug Administration in the United States, the FDA. OpenAI apparently is meeting with a bunch of officials there. They're talking about essentially how that agency is going to use AI to speed up how they're testing drugs. So according to the report, OpenAI has been discussing this and they're calling the project Coder GPT or CDER GPT. Sorry, not Coder cd. Er, GPT, which essentially is a tool for the center for Drug Evaluation. And this, you know, the CDE essentially regulates over the counter and prescription drugs in the United States. Apparently some associates from doge, the Department of Government Efficiency, have been part of talks with this as well. If you. It's definitely like a. It's a pretty common thing for drug development to take an Insane amount of time, you know, up to a decade, sometimes 10 years to complete trials for some, you know, popular drugs. Very expensive, very costly, takes a long time. OpenAI is hoping to work with the FDA to essentially accelerate a portion of that timeline. Obviously not everything, like, it's got to go through a lot of tests and things, it's got to be pretty rigorous, but there is a lot that AI can help with. We've seen a lot where people have used AI to help with drug discovery and other things. So this looks to be the angle they're trying to take towards this. AI essentially is going to try to make this whole drug discovery process a little bit faster and a lot of the administration stuff faster as well. So this is very interesting and I think we're going to start seeing hopefully faster drug time turnarounds. This is going to lead to a lot of innovation and a lot of exciting new things on the market there. So hopefully diseases and other things will be able to be cured faster or researched quicker or, you know, we will come to better outcomes on all of that. So very interesting everything OpenAI is doing with the government, with, you know, the FDA. I'm super excited about everything we're seeing there. If you're interested in trying out all of the different AI models from OpenAI, go check out AI box AI you get access to that anthropic Claude 11 labs, all of the top AI models all in one place for only $20 a month. So I love to have you as a member of my software AI box. The links in the description for that. Hope you learned something new from this episode. If you did, I would love it if you could leave a rating and review wherever you get. Your podcast helps the show out a ton to get shown to new people. Thanks so much for tuning in and I will catch you next time.